Spherix Global Insights

April 07, 2017

RealTime Dynamix™: Hyperkalemia (Neph) US Q2

The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016.

RealTime Dynamix™: Hyperkalemia provides a detailed and timely look at how the hyperkalemia market is evolving with these new therapeutic options. The quarterly updates allow for close-quarters monitoring of key performance metrics, focused on in-dustry contact rates, brand gains and losses, key launch metrics for Veltassa (and later ZS-9) and awareness of products in development. By incorporating fixed measures with variable content that is refreshed monthly, RealTime Dynamix enables you to react to changes in the market and capitalize on opportunities for your brand. The rapid field-to-insight turnaround, highly relevant content and unparalleled knowledge of the hyperkalemia market makes this an essential tool for companies competing in the space as well as those with near term plans to enter it.

Download Report Overview

About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Telephone: (800) 661-0571
Email: [email protected]